Benzene Sulfonamide Thiazole and Oxazole Compounds

Abstract

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

That which is claimed is: 
     
         1 . A compound of formula (I) 
       
         
           
           
               
               
           
         
         wherein: 
         a is 0, 1, 2 or 3; 
         each R 1  is the same or different and is independently selected from halo, alkyl, haloalkyl, —OR 6 , —CO 2 R 6 , —NR 6 R 7 , and —CN; 
         Ring A is selected from C 3-6 cycloalkyl, phenyl, 5-6 membered heterocycle and 5-6 membered heteroaryl, said heterocycle and said heteroaryl each having 1 or 2 heteroatoms selected from N, O and S; 
         each of Q 1 , Q 2 , Q 3  and Q 4  is CH, C—R 2  or N, wherein not more than one of Q 1 , Q 2 , Q 3 , and Q 4  is N; 
         each R 2  is the same or different and is independently selected from halo, alkyl, haloalkyl, and —OR 6 ; 
         W is selected from —O— and —S—; 
         R 3  is selected from H, alkyl, haloalkyl-, -alkylene-OH, —NR 6 R 7 , —C 3-6 cycloalkyl, -alkylene-C(O)—OH, -alkylene-NH 2 , and Het;
 wherein said R 3  C 3-6 cycloalkyl is optionally substituted with 1 or 2 substituents which are the same or different and are independently selected from halo, C 1-3 alkyl, haloC 1-3 alkyl, OH, O—C 1-3 alkyl, oxo, S(C 1-3 alkyl), SO 2 , NH 2 , N(H)C 1-3 alkyl and N(C 1-3 alkyl) 2 ; 
 Het is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N, O and S and optionally substituted with 1 or 2 substituents which are the same or different and are each independently selected from halo, C 1-3 alkyl, haloC 1-3 alkyl, O—C 1-3 alkyl, C 1-3 alkylene-O—C 1-3 alkyl, OH, C 1-3 alkylene-OH, oxo, SO 2 (C 1-3 alkyl), C 1-3 alkylene-SO 2 (C 1-3 alkyl), NH 2 , N(H)C 1-3 alkyl, N(C 1-3 alkyl) 2 , CN, and —CH 2 CN; 
 
         R 4  is selected from H, alkyl, haloalkyl, alkenyl, —OR 6 , —R 5 —OR 6 , —R 5 —CO 2 R 6 , —R 5 —SO 2 R 6 , —R 5 —Het, —R 5 —C(O)-Het, —N(H)R 8 , —N(CH 3 )R 8 , and —R 5 —NR 6 R 7 ; 
         each R 5  is the same or different and is independently C 1-4 alkylene; 
         each R 6  and each R 7  is the same or different and is independently selected from H, alkyl, haloalkyl, —C(O)-alkyl, and —C(O)-cycloalkyl; 
         R 8  is selected from H, alkyl (optionally substituted by —OH), haloalkyl, C 3-6 cycloalkyl, —R 5 —C 3-6 cycloalkyl, Het 2 , —R 5 —Het 2 , —R 5 —OR 6 , —R 5 —O—R 5 —OR 6 , —R 5 —C(O) 2 R 6 , —R 5 —C(O)NR 6 R 7 , —R 5 —N(H)C(O)—R 6 , —R 5 —N(H)C(O)—R 5 —OR 6 , —R 5 —N(H)C(O) 2 —R 6 , —R 5 —NR 6 R 7 , —R 5 —S(O) 2 R 6 , —R 5 —CN, and —R 5 —N(H)S(O) 2 R 6 ;
 wherein said R 8  C 3-6 cycloalkyl is optionally substituted with 1 or 2 substituents which are the same or different and are independently selected from halo, C 1-3 alkyl, haloC 1-3 alkyl, OH, O—C 1-3 alkyl, oxo, S(C 1-3 alkyl), SO 2 (C 1-3 alkyl), NH 2 , N(H)C 1-3 alkyl and N(C 1-3 alkyl) 2 , and N(H)SO 2 C 1-3 alkyl; and 
 Het 2  is a 4-6 membered heterocycle having 1 or 2 heteroatoms selected from N, O and S and optionally substituted with 1, 2, 3, 4 or 5 C 1-3 alkyl or 1 or 2 substituents which are the same or different and are each independently selected from halo, C 1-3 alkyl, haloC 1-3 alkyl, O—C 1-3 alkyl, C 1-3 alkylene-O—C 1-3 alkyl, OH, C 1-3 alkylene-OH, oxo, SO 2 (C 1-3 alkyl), C 1-3 alkylene-SO 2 (C 1-3 alkyl), NH 2 , N(H)C 1-3 alkyl, N(C 1-3 alkyl) 2 , N(H)SO 2 C 1-3 alkyl, C(O)(C 1-3 alkyl), CO 2 (C 1-4 alkyl), CN, and —CH 2 CN; 
 
         and pharmaceutically acceptable salts thereof.